| PATENT ASSIGNEE'S COUNTRY | USA |
| UPDATE | 07.00 |
| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | 11.07.00 |
| PATENT TITLE |
Use of neuregulins as modulators of cellular communication |
| PATENT ABSTRACT | The present invention relates to methods of affecting cellular communication in a vertebrate. The communication is affected by the administration of a neuregulin to a vertebrate, where the neuregulin interacts with a first cell type which results in the production of a product (i.e., Product A). This product, in turn, affects the function of a second cell type. Methods are disclosed in which the affect in function of the second cell type, described above, results in the production of a second product (i.e., Product B) which, in turn, can affect the function of the first cell type or a third cell type. Additional methods are included for treatment of disorders involving an altered or inadequate level of production of a product involved in cellular communication |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | 17.11.94 |
| PATENT REFERENCES CITED |
Peles et al. (1993) Bioessays 15, 815-824. Danilenko et al. (1994) FASEB Journal 8 (4-5), A535. Brockes, J.P. et al., Development in the Nervous System, 309-327, 1980, The neuron as a Source of Mitogen: Its Influence on the Proliferation of Glial and Non-neural Cells. Danilenko et al., FASEB Journal, vol. 8 Numbers 4-5, A535, 1994, Neu Differentiation Factor (NDEF) Accelerates Epidermal Migration and Differentiation in Excisional Wounds. Marshall, Special News Report, vol. 269, 1050-1055, Aug. 25, 1995, Gene Therapy's Growing Pains. Verdi, et al, Neuron, vol. 16, 515-527, Mar. 1996, A Reciprocal Cell-Cell Interation Mediated by NT-3 and Neuregulins Controls the Early Survival and Development of Sympathetic Neuroblasts. Yao et al, Proc. Natl. Acad. Sci. USA, vol. 89, 3357-3361, Apr. 1992, Expression of Human Factor IX in Mice after Injection of Genetically Modified Myoblasts. Cheema, et al, Journal of Neuroscience Research, vol. 37, 213-218, 1994, Leukemia Inhibitory Factor Prevents the Death of Axotomised Sensory Neurons in the Dorsal Root Ganglia of the Neonatal Rat. Curtis, et al, Neuron, vol. 12, 191-204, 1994, Retrograde Axonal Transport of LIF is Increased by Peripheral Nerve Injury: Correlation with Increased LIF Expression in Distal Nerve. Fann, et al, Journal of Neurochemistry, vol. 61, 1349-1355, 1993, A Novel Approach to Screen for Cytokine Effects on Neuronal Gene Expression. Grinspan, et al, The Journal of Neuroscience, vol. 16, 6107-6118, Axonal Interactions Regulate Schwann Cell Apoptosis in Developing Peripheral Nerve: Neuregulin Receptors and the Role of Neuregulins. Hefti, Journal of Neurobiology, vol. 25, No. 11, 1418-1435, 1994, Neurotrophic Factor Therapy for Nervous System Degenerative Diseases. Henderson, et al, Science, vol. 266, 1062-1064, 1994, GDNF: A Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle. Hughes, et al, Journal of Neuroscience Research, vol. 36, 663-671, 1993, Members of Several Gene Families Influence Survival of Rat Motoneurons in Vitro and In Vivo. Kotzbauer, et al, Neuron, vol. 12, 763-773, 1994, Postnatal Development of Survival Responsiveness in Rat Sympathetic Neurons to Leukemia Inhibitory Factor and Ciliary Neurotrophic Factor. Lin, et al, Science, vol. 260, 1130-1132, 1993, GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dpaminergic Neurons. Mahanthappa, et al, The Journal of Neuroscience, vol. 16, 4673-4683, 1996, Glial Growth Factor 2, a Soluble Neuregulin, Directly Increases Schwann Cell Motility and Indirectly Promotes Neurite Outgrowth. Martinou, et al, Neuron, vol. 8, 737-744, 1992, Cholinergic Differentiation Factor (CDF/LIF) Promotes Survival of Isolated Rat Embryonic Motoneurons in Vitro. Oppenheim, et al., Nature, vol. 373, 344-346, 1995, Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Pinkas-Kramarski, Proc. Natl. Acad. Sci. USA, vol. 91, 9387-9391, 1994, Brain neurons and glial cells express Neu differentiation factor/heregulin: A survival factor for astrocytes. Qin-Wei, et al, The Journal of Neuroscience, vol. 14, 7629-7640, 1994, Cell Death of Spinal Motoneurons in the Chick Embryo following Deafferentation: Rescue Effects of Tissue Extracts, Soluble Proteins, and Neurotrophic Agents. Syroid, et al, Proc. Natl. Acad. Sci. USA, vol. 93, 9229-9234, 1996, Cell Death in the Schwann Cell Lineage and its Regulation by Neuregulin. Trachtenberg, et al, Nature, vol. 379, 174-176, 1996, Schwann Cell Apoptosis at Developing Neuromuscular Junctions is Regulated by Glial Growth Factor. Xie, et al, Biotechniques, vol. 11, No. 3, 325-327, 1991, Rapid, Small-Scale RNA Isolation from Tissue Culture Cells. Yamamori, et al, Science, vol. 246, 1412-1416, 1989, The Cholinergic Neuronal Differentiation Factor from Heart Cells is Identical to Leukemia Inhibitory Factor. Yan, et al, Nature, vol. 373, 341-344, 1995, In Vivo Neurotrophic Effects of GDNF on Neonatal and Adult Facial Motor Neurons. Yuen, et al., Annals of Neurology, vol. 40, No. 3, 340-354, 1996, Therapeutic Potential of Neurotrophic Factors for Neurological Disorders. |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What is claimed is: 1. A method of affecting cellular communication between neuronal-associated cells and neuronal cells in a vertebrate, comprising administration of a neuregulin with p185.sup.erbB2, p185.sup.erbB3 or p185.sup.erbB4 binding activity to said vertebrate wherein said neuregulin interacts with said neuronal-associated cells, resulting in production of at least one neurotrophic agent by said neuronal-associated cells and said neurotrophic agent or agents affect the mitotic activity, survival, differentiation or neurite outgrowth of said neuronal cells. 2. A method of claim 1 wherein said vertebrate is a human. 3. A method of claim 1 wherein said neuronal-associated cells are nervous system support cells. 4. A method of claim 3 wherein said nervous system support cells are glial cells. 5. A method of claim 1 wherein said neuronal-associated cells are sensory organ cells. 6. A method of claim 1 wherein said neuronal-associated cells are muscle cells. 7. A method of claim 1 wherein said neuronal cells are cholinergic neurons. 8. A method of claim 1 wherein said neuronal cells are non-cholinergic neurons. 9. A method of claim 1 wherein said neuregulin is rhGGF2. 10. A method of affecting cellular communication between neuronal-associated cells and neuronal cells in the peripheral nervous system of a vertebrate, comprising administration of a neuregulin with p185.sup.erbB2, p185.sup.erbB3 or p185.sup.erbB4 binding activity to said vertebrate wherein said neuregulin interacts with said neuronal-associated cells, resulting in production of at least one neurotrophic agent by said neuronal-associated cells and said neurotrophic agent or agents affect the mitotic activity, survival, differentiation or neurite outgrowth of said neuronal cells. 11. A method of claim 10 wherein said neuronal associated cells are Schwann cells. 12. A method of claim 10 wherein said neuronal-associated cells are muscle cells. 13. A method of claim 10 wherein said neuronal-associated cells are skeletal muscle cells. 14. A method of claim 10 wherein said neuronal-associated cells are cardiac muscle cells. 15. A method of claim 10 wherein said neuronal-associated cells are smooth muscle cells. 16. A method of claim 10 wherein said neuronal-associated cells are sensory organ cells. 17. A method of claim 10 wherein said neuronal cells are cholinergic neurons. 18. A method of claim 10 wherein said neuronal cells are non-cholinergic neurons. 19. A method of treating a neurological disorder involving neuronal degeneration in the peripheral nervous system of a mammal, comprising administration of a therapeutically effective amount of a neuregulin with p185.sup.erbB2, p185.sup.erbB3 or p185.sup.erbB4 binding activity to said mammal wherein said neuregulin interacts with neuronal-associated cells, resulting in the production of at least one neurotrophic agent which affects the mitotic activity, survival, differentiation or neurite outgrowth of neuronal cells. 20. A method of treating peripheral neuropathy and peripheral nerve injury comprising administration of a therapeutically effective amount of a neuregulin with p185.sup.erbB2, p185.sup.erbB3 or p185.sup.erbB4 binding activity wherein said neuregulin interacts with a neuronal-associated cells, resulting in production of at least one neurotrophic agent by said neuronal-associated cells and said neurotrophic agent or agents affect the mitotic activity, survival, differentiation or neurite outgrowth of neuronal cells. -------------------------------------------------------------------------------- |
| PATENT PHOTOCOPY | Available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |